abinScience is a premium life science reagent brand founded in 2023 as a strategic venture of AtaGenix (established in 2011). Backed by over 15 years of expertise in protein and antibody development, abinScience provides researchers worldwide with reliable, high-performance catalog products that accelerate scientific discovery. Our portfolio includes 25,000+ antibodies, 13,000+ recombinant proteins, and 450+ ELISA kits, with specialized collections in VHH nanobodies (800+), in vivo-grade bispecific antibodies, and research-grade biosimilars for ADA and drug monitoring. Supporting research in virology, immunology, and neuroscience.
Leveraging AtaGenix’s proven expertise, our products are developed using advanced technologies, including optimized protein expression systems, de novo antibody discovery platforms, and next-generation antibody engineering supported by AI-assisted design. These proprietary platforms are validated by leading research institutions to ensure consistent and reproducible results.